| This meeting was only intended for healthcare professionals from the UK and Ireland. This meeting was organised and funded by Teva and included mention of Teva product(s). Prescribing Information was available at the meeting and is available in the links below. |
| Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0)207 540 7117, or email uk.safety@tevauk.com. |
Sleep disorders
From Head Start's Annual Meeting, June 2024
Dr Alexander Nesbitt provides an overview of sleep-related headache disorders
Dr Alexander Nesbitt provides an overview of sleep-related headache disorders, including FASPS2, hypnic headache, cluster headache, sleep apnoea headache, and migraine, noting how these conditions range from extremely rare to very common.
He stresses the importance of discussing sleep nuances during consultations to ensure proper investigation and treatment.01 Dr Nesbitt also highlights the significance of optimising sleep in managing migraines.01
Abbreviations
CGRP, calcitonin gene-related peptide; FASPS2, familial advanced sleep phase syndrome-2; HRT, hormone replacement therapy; ICS, integrated care systems; NICE, National Institute for Health and Care Excellence.
Discover more about Head Start's Annual Meeting
Prescribing Information
References
-
Back to contents.
Stanyer EC, Creeney H, Nesbitt AD, Holland PR, Hoffmann J. Subjective Sleep Quality and Sleep Architecture in Patients With Migraine: A Meta-analysis. Neurology. 2021;97(16):e1620-e1631. doi:10.1212/WNL.0000000000012701
This meeting was open to HCPs from the UK and Ireland with an interest in headache and migraine. This meeting was organised and funded by Teva.
Registered in England No. 302461. Registered office: Teva UK Limited, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX
+44 (0) 1977 628500 | www.tevauk.com | Copyright © 2024 Teva UK Limited
Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0) 207 540 7117, or email uk.safety@tevauk.com.
Privacy Policy | Pharmacovigilance Privacy Policy | Terms and Conditions | Accessibility | Reporting Adverse Events